Cleared Special

STAR Apollo™ Mapping System (K253733) - FDA 510(k) Clearance

Class II Cardiovascular device cleared through the Special 510(k) pathway - typically does not require clinical trials.

K253733 · Rhythm AI, Ltd. · Cardiovascular device
Download Printable Device Report (PDF)
Optimized for regulatory review, auditing and printing
Dec 2025
Decision
25d
Days
Class 2
Risk

K253733 is an FDA 510(k) clearance for the STAR Apollo™ Mapping System. Classified as Computer, Diagnostic, Programmable (product code DQK), Class II - Special Controls.

Submitted by Rhythm AI, Ltd. (London, GB). The FDA issued a Cleared decision on December 19, 2025 after a review of 25 days - a notably fast clearance cycle.

This device falls under the Cardiovascular FDA review panel, regulated under 21 CFR 870.1425 - the FDA cardiovascular device oversight framework. As a Special 510(k), this submission covers a manufacturer modification to an existing cleared device rather than a new device introduction.

Device pattern: Iterative device modification. Low regulatory complexity profile. This Special 510(k) clearance confirms that the manufacturer's modifications remained within the established regulatory envelope of the original cleared device.

View all Rhythm AI, Ltd. devices

Submission Details

510(k) Number K253733 FDA.gov
FDA Decision Cleared Substantially Equivalent - Traditional 510(k) (SESE)
Date Received November 24, 2025
Decision Date December 19, 2025
Days to Decision 25 days
Submission Type Special
Review Panel Cardiovascular (CV)
Summary Summary PDF
Third-party Review No - reviewed directly by FDA
Combination Product No
PCCP Authorized No
Regulatory Context
Review time vs. panel average
100d faster than avg
Panel avg: 125d · This submission: 25d
Pathway characteristics
Modification to existing cleared device.

Device Classification

Product Code DQK Computer, Diagnostic, Programmable
Device Class Class 2 - Special Controls
CFR Regulation 21 CFR 870.1425
What this classification means

Class II devices require demonstration of substantial equivalence to a legally marketed predicate device. This pathway does not require clinical trials - it relies on engineering equivalence and performance data. Most Cardiovascular devices follow this clearance model.

Regulatory Peers - DQK Computer, Diagnostic, Programmable

All 183
Devices cleared under the same product code (DQK) and FDA review panel - the closest regulatory comparables to K253733.
SafeBeat Rx App
K251218 · Safebeat Rx, Inc. · Feb 2026
NorthStar™ Mapping System
K252164 · Imricor Medical Systems · Jan 2026
CARTO™ 3 EP Navigation System V9.0 with PIU Plus
K254085 · Biosense Webster, Inc. · Jan 2026
HemoSphere Alta Advanced Monitoring Platform (ALTAALL1
K252533 · Edwards Lifesciences · Dec 2025
DeepRhythmAI
K253141 · Medicalgorithmics S.A. · Dec 2025
Vektor Computational ECG Mapping System (vMap®)
K252429 · Vektor Medical, Inc. · Dec 2025